Development of the Parent-Rated Anxiety Scale for Youth With Autism Spectrum Disorder.


Journal

Journal of the American Academy of Child and Adolescent Psychiatry
ISSN: 1527-5418
Titre abrégé: J Am Acad Child Adolesc Psychiatry
Pays: United States
ID NLM: 8704565

Informations de publication

Date de publication:
09 2019
Historique:
received: 05 06 2018
revised: 03 10 2018
accepted: 06 11 2018
pubmed: 24 2 2019
medline: 24 7 2020
entrez: 24 2 2019
Statut: ppublish

Résumé

Anxiety is common in youth with autism spectrum disorder (ASD). There is no accepted outcome measure for anxiety in this population. Following a series of focus groups with parents of youth with ASD, we generated 72 items (scored 0-3). Parents of 990 youth with ASD (aged 5-17 years; 80.8% male) completed an online survey. Factor analysis and item response theory analyses reduced the content to a single factor with 25 items. Youth with at least mild anxiety (n = 116; aged 5-17 years; 79.3% male) participated in a comprehensive clinical assessment to evaluate the validity and reliability of the 25-item Parent-Rated Anxiety Scale for ASD (PRAS-ASD). In the online sample, the mean PRAS-ASD score was 29.04 ± 14.9 (range, 0-75). The coefficient α was 0.93. The item response theory results indicated excellent reliability across a wide range of scores with low standard errors. In the clinical sample (n = 116), the PRAS-ASD mean was 31.0 ± 15.6 (range, 1-65). Pearson correlations with parent ratings of ASD symptom severity, repetitive behavior, and disruptive behavior ranged 0.33 to 0.66, supporting divergent validity of the PRAS-ASD. Pearson correlation with a parent-rated measure of anxiety used in the general pediatric population of 0.83 supported convergent validity. A total of 40 participants (32 boys, 8 girls; mean age, 11.9 ± 3.4 years) returned at time 2 (mean, 12.2 days) and time 3 (mean, 24.2 days). Intraclass correlation showed test-retest reliabilities of 0.88 and 0.86 at time 2 and time 3, respectively. The 25-item PRAS-ASD is a reliable and valid scale for measuring anxiety in youth with ASD.

Identifiants

pubmed: 30797036
pii: S0890-8567(19)30124-8
doi: 10.1016/j.jaac.2018.10.016
pii:
doi:

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't Validation Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

887-896.e2

Subventions

Organisme : NIMH NIH HHS
ID : R01 MH099021
Pays : United States

Informations de copyright

Copyright © 2019 American Academy of Child and Adolescent Psychiatry. Published by Elsevier Inc. All rights reserved.

Auteurs

Lawrence Scahill (L)

Marcus Autism Center, Emory University School of Medicine, Atlanta, GA. Electronic address: lawrence.scahill@emory.edu.

Luc Lecavalier (L)

Ohio State University, Nisonger Center, Columbus, OH.

Robert T Schultz (RT)

Center for Autism Research, Children's Hospital of Philadelphia and Perelman School of Medicine, University of Pennsylvania, Philadelphia.

Andrea Nichole Evans (AN)

Marcus Autism Center, Emory University School of Medicine, Atlanta, GA.

Brenna Maddox (B)

Center for Autism Research, Children's Hospital of Philadelphia and Perelman School of Medicine, University of Pennsylvania, Philadelphia.

Jill Pritchett (J)

Ohio State University, Nisonger Center, Columbus, OH.

John Herrington (J)

Center for Autism Research, Children's Hospital of Philadelphia and Perelman School of Medicine, University of Pennsylvania, Philadelphia.

Scott Gillespie (S)

Marcus Autism Center, Emory University School of Medicine, Atlanta, GA.

Judith Miller (J)

Center for Autism Research, Children's Hospital of Philadelphia and Perelman School of Medicine, University of Pennsylvania, Philadelphia.

R Toby Amoss (RT)

Marcus Autism Center, Emory University School of Medicine, Atlanta, GA.

Michael G Aman (MG)

Ohio State University, Nisonger Center, Columbus, OH.

Karen Bearss (K)

University of Washington, Seattle.

Kenneth Gadow (K)

State University of New York at Stony Brook, NY.

Michael C Edwards (MC)

Arizona State University, Tempe, AZ.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH